Industry standard

Dieta’s Stool Imaging AI Validated to Exceed Industry Standard in Gastroenterology, Clinical Study Published

Dieta is revolutionizing digestive health with its IBS personalized care platform. The company created the world’s first mobile application with stool image recognition technology, making the measurement of digestive outcomes (poo) objective rather than subjective. The technology has been validated in a clinical trial published at Cedars-Sinaiwhich is more accurate than the current industry standard for patient-reported results.

About the company and the founder:
CEO and Founder, Asaf Krausis Data Scientist and SCI patient, passionate about solving digestive health issues for millions of others who have suffered like him. In 2017, at the height of the severity of its SCIKraus spent all his time outside of work consulting gastroenterologists and other clinicians and experiment with dozens of treatment options. Kraus learned a lot about the painful and confusing journey of a SCI patient. Given his expertise in machine learning as a Data Scientist at Uberhe is convinced that data and AI can help solve some of these problems.

The biggest revelation came years ago when Kraus participated as a subject in a clinical trial, testing an experimental drug. During this experience, he learned how the scientific community measures the outcomes of stool interventions – by asking patients to recall and subjectively rank their stools on the Bristol scale.

As a result of this experience coupled with data science expertise, Dieta has created a mobile app for iOS and Android that allows patients to easily take an image of each bowel movement and instantly categorize objective and accurate health outcomes. digestive. In addition to the Bristol Scale, the Dieta app also classifies several other stool characteristics, including bulk and fragmentation from a single image capture.

Today, the results of a groundbreaking human clinical trial validating Dieta’s stool image recognition technology were published in the American Journal of Gastroenterology.

About the clinical trial:
The trial was conducted by the MAST program (Medically Associated Science and Technology Program) of Cedars-Sinai in Los Angeles. Principal Investigator, dr. Marc Pimentel M.D. is world famous gastroenterologist and researcher, recognized for the discovery of numerous innovations SCI treatments and diagnoses.

Patients recruited by Cedars-Sinai used Dieta’s app to capture stool images before, during, and after taking an experimental drug throughout 2021. Two expert gastroenterology professors then manually graded more of 200 stool images to create a “gold standard” against which to compare Dieta’s results. AI to the current standard of patient-reported classifications.

AI was found to be comparable in accuracy to that of expert gastroenterologists and superior to patients in stool classification.

Numbers:

  • Dieta’s AI was more sensitive (83%) and specific (94%) compared to patients (55% and 71% respectively).
  • Dieta’s AI stool classifications were more correlated (0.71) with patients’ symptom severity scores than even the patients’ own classifications (0.46).

Dr. Pimentel found that “Dieta’s stool image recognition objectified constipation, diarrhea, and normal stools, so there was less subjective patient influence on test results.” The validation study proved that AI was much more accurate than patient self-reporting. “It could be a game-changer in terms of getting a clearer view of the real effects on patient stool outcomes and drug side effects in clinical trials for gastroenterology and beyond,” Dr. Pimentel said.

Dieta is working with other gastrointestinal pharmaceutical companies to adopt stool image recognition technology as a measurement tool to collect better data and truly understand the impact of their medications on stool outcomes.

In addition to proprietary stool imaging AI, Dieta’s patient platform offers so much more. Patients can also take meal photos, track medications and symptoms, and get advice on choosing interventions (treatments) as they strive to improve their digestive health. Patients can also easily share their data with their clinicians for viewing on the Dieta Clinician Portal.

Dieta’s apps have been used by over 7,000 patients. Next month, Dieta plans to launch a patient care service, where patients using the platform can also connect with a unified team of gastroenterologists, dietitians and coaches for advice and care directly in the clinic. Dieta app.

Dieta Health raised $1.9 million in its pre-seed funding round, and is backed by Tech Starsand investors/partners, including Cedars-Sinai (an international leader in gastroenterology), and UnitedHealthcare (the largest healthcare payer in the world).

Dieta’s AI is superior to current standards, and her vision for solving IBS using data, alongside medical advice and personal coaching, is a win-win solution, improving the patient experience and saving time, money and stress.

About Dieta Health: A better way to manage and treat IBS, Dieta uses AI to personalize digestive healthcare for the 11% of the world’s population who suffer from digestive disorders. The first company to validate stool image recognition in a human clinical trial that makes the measurement of digestive (poo) outcomes objective rather than subjective. Dieta is based in Los Angeles and backed by Techstars, UnitedHealthcare (the world’s largest healthcare payer), and Cedars-Sinai (a leading medical center for gastroenterology). Download the app with Android or iOS.

SOURCE Diet Health